NLE Endocrine & Metabolic Nursing — Diabetes Mellitus & Its ComplicationsStudy Notes

Diabetes mellitus is fundamentally a disorder of glucose metabolism arising from insufficient insulin production, insulin resistance, or both. Insulin, secreted by pancreatic beta cells in response to elevated blood glucose, acts as a key that allows glucose to enter cells for energy production. When insulin is absent or ineffective, glucose accumulates in the bloodstream (hyperglycemia) while cells are deprived of their primary fuel source. This creates the metabolic chaos underlying all diabetic complications. Understanding the pathophysiologic distinction between Type 1 and Type 2 diabetes is essential because it determines the entire clinical presentation, management approach, and complication trajectory. Type 1 Diabetes Mellitus occurs from autoimmune destruction of insulin-producing beta cells, resulting in absolute insulin deficiency. This process may take weeks to months to become clinically apparent, though it often progresses rapidly in children and young adults. Because the body has zero capacity to produce insulin, Type 1 patients depend entirely on exogenous insulin replacement for survival—they cannot be managed with diet alone or oral agents. The classic presentation includes rapid onset of the "3 Ps" (polyuria, polydipsia, polyphagia), weight loss despite increased appetite, fatigue, and blurred vision. Type 1 accounts for 5-10% of all diabetes cases but represents the majority of childhood-onset diabetes in developed countries. These patients are at particularly high risk for diabetic ketoacidosis (DKA), an acute and potentially fatal emergency. Type 2 Diabetes Mellitus results from progressive insulin resistance combined with relative (not absolute) insulin deficiency. Insulin resistance means the body's cells do not respond adequately to insulin signaling; although the pancreas initially compensates by producing more insulin, this hyperinsulinemia eventually exhausts beta cell function. Type 2 is strongly associated with obesity, sedentary lifestyle, advancing age, and genetic predisposition, though it is increasingly seen in young people and children in the context of rising obesity rates. Unlike Type 1, many Type 2 patients can initially be managed with lifestyle modification and oral agents, though eventually 30-40% require insulin supplementation. Type 2 patients are prone to hyperglycemic hyperosmolar nonketotic syndrome (HHNS), which develops insidiously over days and typically affects older or debilitated individuals. Gestational Diabetes Mellitus (GDM) is glucose intolerance first recognized during pregnancy, occurring in 2-10% of pregnancies. While often resolving after delivery, GDM significantly increases the mother's lifelong risk of Type 2 diabetes (20-50% within 5-10 years) and carries immediate risks for the fetus and newborn, including macrosomia, neonatal hypoglycemia, and respiratory distress (covered in maternal-newborn nursing modules). Secondary diabetes can develop from pancreatic disease (chronic pancreatitis, cystic fibrosis), endocrine disorders (acromegaly, Cushing's syndrome, hyperthyroidism), medications (corticosteroids, thiazide diuretics, protease inhibitors), and hemochromatosis.

Precise knowledge of diagnostic criteria is essential for NLE success and for identifying undiagnosed diabetes in clinical practice. The American Diabetes Association (ADA) and WHO diagnostic thresholds are standardized globally and are frequently tested on the NLE. Fasting Plasma Glucose (FPG) is measured after a minimum 8-hour fast and is one of the most straightforward diagnostic tests. Normal fasting glucose is 70–100 mg/dL. A fasting glucose of 100–125 mg/dL indicates impaired fasting glucose (IFG), a prediabetic state. Diagnosis of diabetes requires a fasting glucose ≥126 mg/dL on at least two separate occasions, or one fasting glucose ≥126 mg/dL with classic symptoms. Random (Casual) Plasma Glucose is measured without regard to meal timing. A random glucose ≥200 mg/dL combined with classic diabetes symptoms (polyuria, polydipsia, unexplained weight loss) is diagnostic for diabetes on a single test. This is particularly useful in acute settings or when a patient presents with symptoms. Oral Glucose Tolerance Test (OGTT) involves measuring fasting glucose, then giving a 75-gram glucose load and measuring plasma glucose at 2 hours. This test is most sensitive for detecting glucose intolerance and is the gold standard for diagnosing GDM. The 2-hour OGTT result ≥200 mg/dL is diagnostic for diabetes; 140–199 mg/dL indicates impaired glucose tolerance (IGT). Hemoglobin A1c (Glycosylated Hemoglobin) is a measure of average blood glucose over the preceding 2–3 months, formed when glucose binds non-enzymatically to hemoglobin. Normal A1c is <5.7% (or <39 mmol/mol). An A1c of 5.7–6.4% indicates prediabetes. A1c ≥6.5% on two separate occasions is diagnostic for diabetes. A1c is particularly valuable for diagnosis in non-fasting states and for long-term glycemic monitoring; the treatment target for most diabetics is A1c <7% (or <53 mmol/mol). A1c may be falsely low in conditions causing shortened RBC survival (hemolysis, sickle cell disease) and falsely high in iron deficiency. C-peptide Level measures endogenous insulin secretion and is useful in differentiating Type 1 (absent or very low C-peptide) from Type 2 (normal or elevated, indicating residual beta cell function). It is not routinely diagnostic but helps in classification, particularly early in Type 1 disease. Glucose and Ketones in Urine indicate significant hyperglycemia (glucose appears in urine when plasma glucose exceeds the renal threshold, typically ~180 mg/dL) and metabolic stress (ketones indicate fat breakdown). While not diagnostic, ketonuria in the setting of hyperglycemia is a red flag for DKA. In the Philippines, where many patients present late or in acute crisis, the clinical diagnosis is often made using random glucose or fasting glucose combined with symptom assessment. Resources for A1c and OGTT may be limited in provincial settings, making basic FPG and bedside glucose monitoring all the more critical.

Mastery of insulin types and their pharmacokinetic profiles (onset, peak, and duration) is the single most heavily tested concept in diabetes nursing on the NLE. This knowledge is literally lifesaving because the peak time is when hypoglycemia risk is highest. Clinical errors in insulin administration—such as giving rapid-acting insulin without ensuring food is available, or mixing incompatible insulins—directly cause patient harm. Rapid-Acting Insulins (Insulin Lispro, Aspart, Glulisine) are structurally modified human insulins that begin working within 10–15 minutes of subcutaneous injection, peak at 30 minutes to 1.5 hours, and are eliminated within 3–4 hours. These are clear solutions that are injected immediately before (or with) a meal. Because the onset is so rapid, food must be present or hypoglycemia will develop within minutes. Rapid-acting insulins are preferred for meal-time coverage in modern insulin regimens and are also used in insulin pumps. The very short duration means patients must eat regularly spaced meals to maintain glucose stability. Short-Acting (Regular) Insulin is human insulin (non-modified) that begins working 30 minutes to 1 hour after injection, peaks at 2–4 hours, and is effective for 5–8 hours. Regular insulin is clear and is the ONLY insulin preparation that can be given intravenously (critical for DKA and HHNS management via IV drip). Subcutaneously, regular insulin is given 30 minutes before a meal to allow time for absorption. The longer peak window (2–4 hours) compared to rapid-acting insulins means hypoglycemia risk is distributed over a wider time window. Intermediate-Acting Insulin (NPH – Neutral Protamine Hagedorn) has onset of 1–2 hours, peaks strongly at 6–12 hours (a prolonged peak that creates significant hypoglycemia risk), and lasts 12–18 hours. NPH is a CLOUDY/MILKY suspension because the insulin is complexed with protamine and zinc; it must be gently rolled or inverted 8–10 times to resuspend the particles before injection (shaking vigorously causes foam and inaccurate dosing). NPH is given once or twice daily and was historically the backbone of insulin therapy; it is now less common in developed countries but remains widely used in resource-limited settings like the Philippines due to lower cost. The 6–12 hour peak window is a major hypoglycemia risk, particularly overnight if NPH is given in the evening. Long-Acting Insulins (Glargine, Detemir, Degludec) are designed to provide steady, basal insulin coverage with MINIMAL or NO pronounced peak. Glargine has a very gradual onset (1 hour) and provides relatively flat coverage for ~24 hours, with a very subtle peak around 9–12 hours that most clinicians consider negligible. Detemir is shorter-acting (~16–18 hours) and may be given twice daily. Degludec has the longest duration (>42 hours). These are clear solutions that are NEVER mixed with any other insulin (mixing denatures the preparation and destroys the desired pharmacokinetics). Long-acting insulins provide basal coverage and are typically combined with rapid-acting insulins for meal coverage in modern intensive insulin regimens. Because there is no pronounced peak, hypoglycemia risk from the long-acting insulin itself is lower than with NPH, though patients can still become hypoglycemic from the combination of basal + bolus (meal) insulin. Mixture Insulins (e.g., 70/30 NPH/Regular, 75/25 Lispro Protamine/Lispro) combine intermediate and rapid/short-acting insulins in fixed ratios. These come premixed and should never be further mixed with other insulins. They are convenient for patients who struggle with complex insulin regimens but lack the flexibility of separate injections. Critical Insulin Administration Rules for NLE Success: 1. **MIXING INSULINS:** The cardinal rule is "CLEAR before CLOUDY." When combining clear (regular or rapid-acting) insulin with cloudy (NPH), follow this exact sequence: (a) Inject air into the NPH vial FIRST (to avoid introducing regular insulin into NPH); (b) Inject air into the CLEAR vial; (c) Withdraw the desired amount of CLEAR insulin; (d) Without removing the needle, insert it into the NPH vial and withdraw the NPH. This prevents contaminating the clear insulin vial with protamine, which would alter its pharmacokinetics. Lispro and aspart should NOT be mixed with NPH because they have different peak times and the mixture is unreliable. 2. **GLARGINE (and other long-acting) SHOULD NEVER BE MIXED** with any other insulin—premixing denatures the long-acting preparation. 3. **RAPID-ACTING INSULIN AND MEALS:** Rapid-acting insulin must be given WITH or just before a meal. The meal must be ready to eat within 10–15 minutes of the injection, or the patient will develop hypoglycemia as the insulin peaks and glucose-lowering takes effect in the absence of dietary glucose. Patients using rapid-acting insulin (especially those on insulin pumps) must be educated never to give the injection "just in case" a meal might be eaten. 4. **REGULAR INSULIN AND IV ADMINISTRATION:** Regular insulin is the ONLY insulin preparation suitable for intravenous use (it does not precipitate). All other insulins are for subcutaneous (or sometimes intramuscular) use only. In DKA and HHNS, regular insulin is given as a continuous IV drip. 5. **INJECTION SITE ROTATION:** Insulin should be injected within the same anatomic region (abdomen, thigh, arm, buttock) but rotated systematically to prevent **lipohypertrophy** (abnormal fat thickening) and lipodystrophy (fat atrophy). Injection into areas of lipohypertrophy results in unpredictable, delayed, and reduced insulin absorption. The **abdomen** absorbs insulin fastest and most consistently (useful to know for sick patients needing predictable absorption), followed by the arm, thigh, and buttock. 6. **STORAGE AND STABILITY:** The insulin vial in current use is stored at room temperature (safe for 28 days if kept away from direct heat and light). Unopened insulin vials and pens are refrigerated (2–8°C). Insulin should never be frozen or exposed to temperatures >30°C (as in a hot car). 7. **APPEARANCE CHECK:** Regular insulin and all rapid-acting insulins are CLEAR (water-like); NPH is CLOUDY/MILKY. If regular insulin appears cloudy, it should not be used (it may have been contaminated with NPH or other substance during a mixing error).

Oral and injectable non-insulin agents are the cornerstone of Type 2 diabetes management and are frequently tested on the NLE. Understanding the mechanism, hypoglycemia risk, side effects, and contraindications of each class is essential for safe practice. In the Philippines, where many patients present late and access to insulin may be limited in rural areas, these agents are often the initial management approach and may be the only agents available to some patients. Metformin (Biguanide Class) is the first-line oral agent for Type 2 diabetes and is recommended as initial monotherapy for most patients. Metformin decreases hepatic glucose output (gluconeogenesis) and improves insulin sensitivity in muscle tissue. Critically, metformin does NOT stimulate insulin secretion, so it does NOT cause hypoglycemia when used alone—this makes it safe even in patients at risk for missed meals or irregular schedules. Common side effects are gastrointestinal (nausea, diarrhea, anorexia, metallic taste); these are often transient and minimize if the drug is taken with food. The dose is initiated low and titrated gradually to reduce GI upset. A serious but rare adverse effect is lactic acidosis, a potentially fatal condition of lactate accumulation, which occurs primarily in patients with renal impairment (creatinine clearance <30 mL/min), liver disease, or acute illness causing tissue hypoxia. Because of lactic acidosis risk, metformin should be held ("withheld") around radiographic contrast dye procedures (within 48 hours before and 48–72 hours after) and in acute illness, dehydration, or sepsis. Despite these cautions, metformin has an excellent safety profile and is used even in the elderly and in those with modest renal impairment (with dose adjustment). Sulfonylureas (Glipizide, Glyburide, Glimepiride) stimulate insulin secretion from residual pancreatic beta cells. They are effective glucose-lowering agents but carry a significant risk of hypoglycemia (especially glyburide, which has a longer duration) and weight gain from increased insulin levels. These agents are contraindicated in Type 1 diabetes (where beta cells are destroyed and no insulin can be stimulated) and should be used cautiously in elderly patients or those with irregular meal patterns. A notable drug interaction is with alcohol: sulfonylureas can cause a disulfiram-like reaction (flushing, nausea, abdominal discomfort) if combined with alcohol. Sulfonylureas are less commonly used now as monotherapy but remain useful in combination regimens or in resource-limited settings. Meglitinides (Repaglinide, Nateglinide) are rapid-acting insulin secretagogues taken immediately before meals. They are structurally distinct from sulfonylureas but work similarly by triggering beta cells to release insulin. Because of their rapid onset and short duration, they must be taken WITH meals (if a meal is skipped, the dose should be skipped to avoid hypoglycemia). Meglitinides are useful in patients with erratic meal timing, but hypoglycemia and weight gain are concerns. They are less commonly used than other agents. Thiazolidinediones (Pioglitazone, Rosiglitazone) increase insulin sensitivity in muscle and fat tissue by activating PPAR-gamma nuclear receptors, effectively reducing insulin resistance. Thiazolidinediones can be used alone or in combination with other agents and do NOT directly cause hypoglycemia. Major side effects include fluid retention (which can precipitate or worsen heart failure—contraindicated in NYHA Class III–IV), weight gain, and hepatotoxicity (liver enzymes must be monitored, though severe hepatotoxicity is rare). Thiazolidinediones increase risk of bone fractures, particularly in women. They take 4–8 weeks to reach full effect. Rosiglitazone has been withdrawn from many markets due to cardiovascular concerns, but pioglitazone remains available. Dipeptidyl Peptidase-4 (DPP-4) Inhibitors (Sitagliptin, Linagliptin, Saxagliptin) increase glucagon-like peptide-1 (GLP-1) levels by inhibiting the enzyme DPP-4 that breaks down GLP-1. GLP-1 enhances insulin secretion in response to glucose and suppresses glucagon, resulting in modest glucose lowering. DPP-4 inhibitors are weight-neutral and do not directly cause hypoglycemia (hypoglycemia risk exists only in combination with other glucose-lowering agents). They are convenient (oral, once daily) and well-tolerated, with minimal side effects beyond occasional upper respiratory infections. Cost and less robust glucose-lowering compared to other agents limit their first-line use in resource-limited settings. Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors (Empagliflozin, Dapagliflozin, Canagliflozin – ending in "gliflozin") act on the kidneys to increase urinary glucose excretion, thereby lowering blood glucose. They are unique in that they lower glucose independent of insulin, work when renal function is adequate, and have the added benefit of modest weight loss and blood pressure reduction. However, SGLT2 inhibitors carry risks of genital and urinary tract infections (from high urinary glucose), euglycemic DKA (DKA with a near-normal or only modestly elevated glucose, making it easy to miss clinically), and rare cases of fournier gangrene (necrotizing fasciitis of the genitals). Despite these rare risks, SGLT2 inhibitors have cardiovascular and renal protective effects and are increasingly used. They should be held during acute illness or when fasting is planned. Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists (Exenatide, Liraglutide, Semaglutide – ending in "tide") are injectable agents (once weekly or daily, depending on the formulation) that mimic GLP-1, enhancing insulin secretion and suppressing glucagon in a glucose-dependent manner. GLP-1 agonists promote weight loss (5–10 lbs typically), improve cardiovascular outcomes, and reduce hypoglycemia risk. Side effects are primarily gastrointestinal (nausea, vomiting, diarrhea), which often improve over time. Cost is higher than oral agents, limiting access in resource-limited settings. GLP-1 agonists are increasingly recommended for patients with established cardiovascular disease or those needing weight loss. Combination Therapy: Most Type 2 diabetics eventually require multiple agents to achieve glycemic targets. Metformin + a sulfonylurea, or metformin + a DPP-4 inhibitor, or metformin + a GLP-1 agonist, or metformin + an SGLT2 inhibitor are common combinations. The goal is to use agents with complementary mechanisms and minimize hypoglycemia risk. If glycemic targets are not met with oral agents, insulin is added (often starting with long-acting basal insulin, then adding rapid-acting boluses if needed).

Hypoglycemia (blood glucose <70 mg/dL) is the most common acute medical emergency in diabetic patients and is directly caused by excessive insulin relative to glucose intake and utilization. Unlike hyperglycemic emergencies (DKA, HHNS) which develop over hours or days, hypoglycemia onset is rapid—minutes—making it immediately life-threatening. A conscious patient with mild hypoglycemia can deteriorate to seizures and coma within 15–30 minutes if not treated. Understanding recognition, immediate management, and prevention is critical for NLE success and clinical safety. Pathophysiology: Hypoglycemia activates the sympathetic nervous system ("cold and clammy" symptoms) and triggers counter-regulatory hormone release (glucagon, epinephrine, cortisol, growth hormone). These responses attempt to raise blood glucose by stimulating hepatic glucose output. If hypoglycemia is prolonged or severe (glucose <54 mg/dL), counter-regulatory mechanisms may fail, and the brain becomes glucose-deprived, causing seizures and loss of consciousness. Clinical Recognition – The "Cold and Clammy" Presentation: Adrenergic (Sympathetic) Symptoms occur first and are the patient's warning signs: shakiness/tremor, palpitations, tachycardia, diaphoresis (profuse sweating that feels "cold and clammy"), anxiety, nervousness, hunger, and a sense of dread. These symptoms prompt the patient to seek food if conscious. In Type 1 diabetes or patients on insulin, these warning signs are usually prominent and allow self-treatment. Neuroglycopenic (Brain-Glucose-Deprived) Symptoms occur as hypoglycemia worsens or is prolonged: difficulty concentrating, confusion, irritability, blurred vision, slurred speech, inappropriate behavior (acting "drunk" or silly), headache, diplopia, and eventually seizures and loss of consciousness. Importantly, patients with long-standing diabetes may develop **hypoglycemia unawareness** (a reduced or absent sympathetic response to hypoglycemia), so they skip the adrenergic warning signs and go directly to altered mental status with no warning. This is extremely dangerous because the patient does not realize they need to eat until they are already confused and unable to help themselves. Immediate Management – The "Rule of 15": For a conscious patient able to swallow: 1. **TREAT IMMEDIATELY:** Give ~15 grams of FAST-ACTING CARBOHYDRATE. Examples: ½ cup (4 oz) of fruit juice or regular (non-diet) soda, 3–4 glucose tablets, 1 tablespoon of honey, 5–6 hard candies, 2 tablespoons of raisins, or a commercial glucose gel. Avoid chocolate or fat-containing foods (fat slows absorption; not useful for rapid glucose correction). Do NOT give regular meals—hypoglycemia requires rapid glucose, not protein/fat. 2. **RECHECK GLUCOSE IN 15 MINUTES:** If the initial glucose is still <70 mg/dL or symptoms persist, repeat the 15 grams of carbohydrate. Repeat every 15 minutes until blood glucose is >70 mg/dL and symptoms resolve. 3. **LONG-ACTING FOLLOW-UP:** Once the acute hypoglycemia is corrected, provide a meal or snack with protein and complex carbohydrates (e.g., bread with peanut butter, crackers with cheese, or a regular meal if one is due) to prevent recurrence. This longer-acting carbohydrate+ protein combination sustains glucose elevation for hours. For an Unconscious or Unable-to-Swallow Patient: **NEVER attempt oral feeding** (risk of aspiration). In a hospital/clinic setting: **IV dextrose (D50W – 50% dextrose)** is given rapidly, typically 25–50 mL IV push, which raises blood glucose within seconds. In community/home settings: **Intramuscular or subcutaneous glucagon** is administered (1 mg for adults, 0.5 mg for children <20 kg). Glucagon is a hormone that stimulates hepatic glucose release; it works within 10–15 minutes and is effective in most conscious or semi-conscious patients. Caregivers are taught to recognize severe hypoglycemia and administer IM glucagon; emergency services should also be called. Oral glucose should not be forced into an unconscious patient's mouth (aspiration risk). Postman hypoglycemia measures should address the underlying cause (insulin dose too high, insufficient food intake, increased activity, alcohol consumption) and educate the patient on prevention. Special Populations: Children with diabetes: Hypoglycemia in children is particularly dangerous because they cannot reliably recognize symptoms and may not communicate their distress. Teachers, caregivers, and daycare providers must be trained to recognize hypoglycemia and how to administer glucose or glucagon. Elders: Age-related renal and hepatic impairment may alter glucose metabolism; hypoglycemia-induced confusion is easily mistaken for dementia; sulfonylureas carry higher hypoglycemia risk in this group. Night Shift Workers and Drivers: Hypoglycemia while driving or working at night is especially hazardous; close glucose monitoring and meal/snack planning are essential. Hypoglycemia Unawareness: Patients with long-standing diabetes (especially Type 1) may lose the ability to sense hypoglycemia approaching (due to blunted sympathetic response). These patients are at very high risk for severe, unrecognized hypoglycemia and may benefit from continuous glucose monitoring systems that alert them to low glucose values.

Diabetic Ketoacidosis (DKA) and Hyperglycemic Hyperosmolar Nonketotic Syndrome (HHNS, also called Hyperglycemic Hyperosmolar State or HHS) are the two life-threatening hyperglycemic emergencies. Both present with severe hyperglycemia and dehydration, but their pathophysiology, severity, and management differ critically. Distinguishing between them on the NLE and in clinical practice is essential—this is high-stakes content where errors harm patients. **DIABETIC KETOACIDOSIS (DKA):** Pathophysiology: DKA occurs from absolute or severe insulin deficiency, typically in Type 1 diabetic patients. Without insulin, glucose cannot enter cells, and the body perceives starvation despite high blood glucose (a paradox called "glucose-deprived state"). To obtain energy, the body rapidly breaks down fat for fuel via lipolysis. Fat breakdown produces free fatty acids, which the liver converts to ketone bodies (acetoacetate, beta-hydroxybutyrate, acetone). Ketones accumulate faster than they can be utilized or excreted, causing metabolic ACIDOSIS (pH <7.35, bicarbonate typically <15 mEq/L). The resulting combination of hyperglycemia + metabolic acidosis + ketonemia = DKA. Triggers and Onset: DKA is triggered by infection (most common, including UTI, pneumonia), missed or inadequate insulin doses, new-onset Type 1 diabetes, acute stress (MI, stroke, surgery), or medications (corticosteroids, SGLT2 inhibitors—euglycemic DKA). Onset is typically ACUTE to SUBACUTE—hours to ~24 hours. Clinical Presentation of DKA: - **Hyperglycemia:** typically 250–600 mg/dL (though can be >1,000 mg/dL) - **KETONES in blood and urine:** Beta-hydroxybutyrate (in serum) or acetone/ketones in urine; blood ketone testing is more sensitive and is preferred in modern practice - **Metabolic ACIDOSIS:** pH <7.35, bicarbonate <15 mEq/L, anion gap >12 - **Kussmaul respirations:** Deep, rapid, labored breathing (the body's attempt to blow off CO₂ and partially correct acidosis by hyperventilation); patient may appear to be "gasping for air" - **Fruity/acetone-smelling breath:** From acetone (exhaled ketone body); smells like rotten fruit or nail polish remover - **Dehydration:** From osmotic diuresis (high glucose causes glucose to be filtered into urine, pulling water with it) - **GI symptoms:** Nausea, vomiting, abdominal pain (can be severe and mimic acute abdomen; this sometimes leads to unnecessary abdominal surgery) - **Altered mental status:** from metabolic acidosis and dehydration; can range from lethargy to confusion to coma - **Vital signs:** Tachycardia, tachypnea (Kussmaul), low blood pressure (from dehydration), sometimes hypothermia **HYPERGLYCEMIC HYPEROSMOLAR NONKETOTIC SYNDROME (HHNS/HHS):** Pathophysiology: HHNS occurs in Type 2 diabetics who have enough (residual) insulin to prevent ketosis but insufficient insulin to prevent extreme hyperglycemia. Glucose rises to 600–1,200+ mg/dL (much higher than in DKA), causing severe osmotic diuresis and profound fluid loss. Unlike DKA, the modest residual insulin is enough to prevent significant fat breakdown and ketone accumulation, so metabolic acidosis is absent or minimal (pH remains near-normal ~7.35–7.45). The combination of extreme hyperglycemia + profound dehydration + high serum osmolality (typically >320 mOsm/kg, vs. normal ~300) is the hallmark. Triggers and Onset: HHNS is triggered by infection (UTI, pneumonia, sepsis), acute stress, medications (corticosteroids, diuretics), inadequate fluid intake, or non-compliance with diabetes regimen. Onset is typically INSIDIOUS and GRADUAL—DAYS to weeks. This delayed onset and lack of dramatic symptoms (no fruity breath, no Kussmaul) means HHNS is often diagnosed late or in extremis. Clinical Presentation of HHNS: - **EXTREME hyperglycemia:** often >600 mg/dL, can exceed 1,200 mg/dL - **NO significant ketosis:** NO or minimal ketonuria/ketonemia; blood pH is near-normal (~7.35–7.45, not acidotic) - **PROFOUND dehydration:** from massive osmotic diuresis; fluid deficit often 8–12 liters (vs. 5–8 liters in DKA) - **HIGH serum osmolality:** typically >320 mOsm/kg (a key distinguishing lab value) - **Normal or minimal respiratory symptoms:** NO Kussmaul respirations (because no acidosis to compensate for), NO fruity breath (because no ketones) - **Severe neurologic changes:** altered mental status is profound and often more dramatic than in DKA; confusion, lethargy, disorientation, seizures, coma - **Often diagnosed in elderly or disabled patients:** HHNS typically affects older Type 2 diabetics, nursing home residents, patients with reduced thirst sensation or mobility, or those unable to access fluids - **Higher mortality:** 5–15% mortality (vs. 1–5% for DKA) because of extreme dehydration, advanced age, and delayed diagnosis **DKA vs. HHNS — Side-by-Side Comparison:** | Feature | **DKA** | **HHNS** | |---|---|---| | **Type of DM** | Type 1 (or rarely Type 2 with severe insulin lack) | Type 2 (residual insulin present) | | **Patient Profile** | Usually younger, lean | Usually older, overweight | | **Glucose Level** | Typically 250–600 mg/dL | Typically 600–1,200+ mg/dL | | **Ketones/Acidosis** | **PRESENT (blood ketones +, urine ketones +, pH <7.35, HCO3 <15)** | **ABSENT/MINIMAL (no significant ketones, pH ~7.35–7.45, HCO3 normal/low-normal)** | | **Osmolality** | Elevated (~310–320) | **VERY HIGH (>320, often 330–380)** | | **Kussmaul Respirations** | **PRESENT (deep, rapid breathing; fruity breath)** | **ABSENT (breathing normal)** | | **Onset** | Acute to subacute (hours to ~24 hr) | **Insidious/gradual (days to weeks)** | | **GI Symptoms** | Nausea, vomiting, abdominal pain | Often absent or minimal | | **Neurologic Changes** | Mild to moderate (lethargy to confusion) | **PROFOUND (coma common)** | | **Fluid Deficit** | ~5–8 liters | **~8–12+ liters** | | **Mortality** | 1–5% | **5–15%** | | **Triggers** | Infection, missed insulin, new-onset DM, stress, SGLT2i | Infection, non-compliance, inadequate fluid intake, stress | **MANAGEMENT OF DKA AND HHNS (Priorities Are the Same):** The treatment approach for both DKA and HHNS follows the same general sequence, though the severity of each parameter differs. Priority 1: **IV FLUID REPLACEMENT — 0.9% NORMAL SALINE (NOT hypotonic fluids)** - This is the FIRST intervention and is the single most important step for both DKA and HHNS. - Profound dehydration is present in both conditions; correction of dehydration alone can lower blood glucose by 20–30% via improved perfusion and recovery of renal function. - Initial IV normal saline (0.9%) is given rapidly: typically 1–1.5 liters over the first 1–2 hours (or even faster if hypotensive), then 250–500 mL/hr based on vital signs, urine output, and clinical response. - **DO NOT give hypotonic fluids (0.45% saline or D5W)** early; these can cause cerebral edema, especially in children. Once glucose reaches ~200–250 mg/dL, dextrose is added to prevent hypoglycemia (see Priority 4 below). - Monitor for signs of over-hydration (jugular venous distension, pulmonary edema, weight gain); older patients and those with heart/kidney disease are at higher risk. - Electrolyte abnormalities (Na, Cl, K) often develop during rehydration; monitor electrolytes and adjust fluids accordingly. Priority 2: **REGULAR INSULIN — Continuous IV Infusion** - Once fluids are started and IV access is secure, regular insulin is given as a continuous IV drip (regular insulin is the ONLY insulin suitable for IV use). - Loading dose: controversial and often omitted. Some protocols give a 0.1 unit/kg IV bolus, but this is not universally recommended. - Continuous infusion: typically 0.1 units/kg/hr (e.g., a 70 kg patient receives ~7 units/hr). The dose is adjusted based on glucose response; goal is to lower glucose by ~50–100 mg/dL per hour. - In DKA: insulin is essential to stop ketone production and correct acidosis. As insulin levels rise, the body stops breaking down fat, ketone production ceases, and the existing ketones are metabolized (acid clears). - In HHNS: insulin is needed to lower the extreme hyperglycemia and restore cell glucose uptake; insulin infusion is often slightly lower initially because the goal is a gradual glucose decline (too-rapid a drop can cause cerebral edema and hyperglycemia rebound). - Potassium is added to the infusion once K levels are known (see Priority 3 below). **Insulin is NOT given if serum potassium is dangerously low (<3 mEq/L)** without concurrent potassium replacement, because insulin will drive K into cells and cause fatal hypokalemia. Priority 3: **POTASSIUM REPLACEMENT — This is the NLE "Trick Question" Classic** This is where many nurses make errors on exams, so pay close attention: **The Potassium Paradox:** In DKA and HHNS, total body potassium is DEPLETED (from osmotic diuresis, vomiting, diarrhea). However, the **serum potassium at presentation may appear NORMAL or even HIGH.** Why? Because acidosis (in DKA) and dehydration cause potassium to shift OUT of cells into the serum, masking the total-body deficit. Once you start insulin and IV fluids, insulin drives potassium BACK INTO the cells, serum potassium FALLS, and hypokalemia (often severe) develops within hours if potassium is not repleted. **Clinical Rules:** - **If serum K is NORMAL (3.5–5 mEq/L) or HIGH (>5 mEq/L) at diagnosis:** DO NOT give potassium initially. Start monitoring K closely and prepare to add potassium to the IV fluids once K begins to fall (which will happen as insulin works). - **If serum K is LOW (<3.5 mEq/L) at diagnosis:** This indicates severe total-body K depletion. Potassium MUST be repleted BEFORE or WITH insulin infusion; giving insulin without potassium in a hypokalemic patient can precipitate fatal cardiac arrhythmias (peaked T waves, prolonged QT, ventricular fibrillation). - **General potassium replacement strategy:** Once serum K is known to be normal or low (or as it falls during treatment), add potassium to the IV fluid (typical dose: 10–20 mEq per 100 mL of IV saline, depending on the serum level and rate of fall). Replace cautiously and monitor with serial serum K levels and continuous cardiac monitor (watch for peaked T waves, widened QRS, prolonged PR intervals—signs of hyperkalemia—or the flat T waves and U waves of hypokalemia). - **Urine output is also critical:** Potassium should only be added once urine output is documented (>30 mL/hr or so) to ensure kidneys can excrete excess potassium. In oliguric patients, potassium replacement must be even more cautious. Priority 4: **DEXTROSE Addition (when glucose reaches ~200–250 mg/dL)** - Once blood glucose falls to approximately 200–250 mg/dL (typically after 2–4 hours of fluid and insulin therapy), dextrose is added to the IV infusion (e.g., switch from normal saline to D5W or add dextrose to normal saline). - Why? This allows the insulin drip to continue (which is still needed to clear ketones and correct acidosis in DKA, or to lower glucose further in HHNS) without causing hypoglycemia or too-rapid a glucose drop (which risks cerebral edema). - The dual infusion (insulin + dextrose-containing fluids) is continued until the patient is metabolically stable, ketosis is cleared (in DKA), and the patient can tolerate oral intake. Priority 5: **Treatment of Underlying Cause** - Infection is the most common trigger of both DKA and HHNS; antibiotics are initiated if infection is suspected (blood cultures, urinalysis, chest X-ray, etc.). - Missed insulin doses are addressed; insulin regimen is optimized. - Medication non-compliance or medication changes are reviewed and corrected. - Acute concurrent illness (MI, stroke, surgery) is managed. **Monitoring During Treatment:** - **Glucose:** Check hourly initially; goal is gradual decline (avoid precipitous drops that risk cerebral edema). - **Electrolytes (Na, K, Cl, HCO3):** Check at baseline, then every 2–4 hours initially; potassium is especially critical. - **pH and pCO2 (ABG):** In DKA, monitor to assess acidosis correction; in HHNS, less critical but still important. - **Serum osmolality:** Especially in HHNS; osmolality >320 is a key diagnostic criterion and a parameter of improvement. - **Vital signs and urine output:** Maintain MAP >65 mmHg (organ perfusion); target urine output 200–300 mL/hr initially. - **Neurologic status:** Altered mental status should gradually improve as metabolic derangement corrects; if it worsens despite treatment, consider other causes (stroke, infection, subdural hematoma). - **Cardiac monitor:** Continuous monitoring for potassium-related arrhythmias (peaked T waves, widened QRS in hyperkalemia; flat T waves, U waves in hypokalemia). **Transition to Subcutaneous Insulin:** - Once the patient is metabolically stable (glucose 200–250 mg/dL, pH >7.3, bicarbonate >15 in DKA; glucose <300 mg/dL and osmolality <315 in HHNS), can tolerate oral intake, and serum K is stable, the IV insulin drip is discontinued. - Subcutaneous insulin is started (typically a basal-bolus regimen: long-acting basal insulin + rapid-acting insulin with meals). - The IV insulin drip should overlap with SC insulin for 1–2 hours (until SC insulin is absorbed) to avoid rebound hyperglycemia. **Special Considerations in the Philippine Context:** - In many Philippine hospitals, especially in provincial areas, access to continuous glucose monitoring and frequent lab work may be limited. Nursing assessment skills (vital signs, mental status, urine output, skin turgor) are crucial for recognizing improvement or deterioration. - IV insulin drips may not be available or may be uncommon in some settings; improvisation (regular insulin SC with frequent glucose checks) may be necessary, though IV is preferred in acute settings. - Patient/family education on preventing DKA (never omit insulin, seek care early in illness, maintain hydration) and HHNS (adequate fluid intake, diabetes compliance, monitoring elderly/disabled family members) is critical in resource-limited settings where delayed diagnosis is common.

While acute complications (hypoglycemia, DKA, HHNS) are immediately life-threatening, chronic complications from years of hyperglycemia are the leading cause of morbidity and mortality in diabetes. These complications are classified as **microvascular** (affecting small blood vessels) or **macrovascular** (affecting large vessels). Understanding their pathophysiology, prevention strategies, and clinical manifestations is central to NLE testing and to long-term patient care. The good news is that tight glycemic control (target A1c <7%) significantly delays or prevents many of these complications. **MICROVASCULAR COMPLICATIONS:** Microvascular complications result from chronic hyperglycemia damaging the small blood vessels supplying the eyes (retina), kidneys, and peripheral nerves. The mechanism involves sustained high glucose levels causing: 1. Accumulation of sorbitol and fructose in cells (via the polyol pathway), drawing in water and causing cell swelling/dysfunction. 2. Non-enzymatic glycosylation of proteins (like hemoglobin → A1c), altering protein structure and function. 3. Increased oxidative stress and inflammation, damaging vessel endothelium. 4. Thickening of the basement membrane of small vessels, reducing nutrient diffusion and impairing blood flow. **Diabetic Retinopathy** - **Definition & Significance:** Progressive damage to the retinal blood vessels, leading to vision loss and blindness. Diabetic retinopathy is the leading cause of adult blindness in developed countries and a major cause in the Philippines. - **Stages:** - *Nonproliferative* (background retinopathy): Microaneurysms, hemorrhages, hard exudates, and cotton-wool spots on fundoscopy; may cause minimal vision loss initially. - *Proliferative*: Neovascularization (abnormal new vessel growth) on the retina or optic disc in response to retinal ischemia; these fragile vessels bleed easily, causing vitreous hemorrhage and sudden vision loss; can lead to retinal detachment. - **Risk Factors:** Duration of diabetes, poor glycemic control (high A1c), hypertension, dyslipidemia, and pregnancy (can accelerate retinopathy). - **Prevention & Management:** Tight glycemic control (A1c <7%), strict blood pressure control, annual eye exams (dilated fundoscopy by an ophthalmologist) to detect early retinopathy before vision loss, photocoagulation (laser therapy) to stop neovascularization, and intravitreal injections of anti-VEGF agents (bevacizumab, ranibizumab) for advanced cases. In the Philippines, access to ophthalmology services may be limited in rural areas; health promotion and referral to eye centers are important nursing roles. **Diabetic Nephropathy** - **Definition & Significance:** Progressive kidney damage leading to proteinuria, declining GFR, and eventual end-stage renal disease (ESRD). Diabetic nephropathy is the leading cause of ESRD worldwide and in the Philippines, where it accounts for ~30–40% of dialysis patients. - **Stages:** - *Stage 1 (Hyperfiltration)*: Increased GFR despite high glucose; kidneys appear enlarged. - *Stage 2 (Silent)*: Microalbuminuria (small amounts of albumin in urine, detectable only by sensitive testing) with normal GFR; no symptoms; this is a critical window for intervention. - *Stage 3–4 (Chronic Kidney Disease)*: Declining GFR, macroalbuminuria (visible proteinuria), rising creatinine, hypertension, edema. - *Stage 5 (ESRD)*: GFR <15 mL/min; dialysis or transplantation required. - **Mechanism:** High glucose damages the glomerular basement membrane and podocytes; hyperfiltration (from high glucose stimulating increased glomerular filtration) worsens damage; proteinuria itself is toxic and perpetuates kidney decline. - **Prevention & Management:** - *Tight glycemic control* (A1c <7%). - *Tight blood pressure control* (target <130/80 mmHg for diabetics with CKD); BP control is arguably more important than glucose control for slowing kidney disease progression. - *ACE inhibitors (e.g., lisinopril, enalapril) or Angiotensin Receptor Blockers (e.g., losartan, valsartan)*: These agents dilate the efferent arteriole of the glomerulus, reducing intraglomerular pressure and slowing proteinuria. They are FIRST-LINE for hypertension in diabetics with nephropathy, regardless of baseline BP (some are given for renal protection even if BP is not elevated). - *Annual screening*: Measure creatinine and eGFR (estimate of glomerular filtration rate), and test for microalbuminuria (urine albumin-to-creatinine ratio or urine dipstick) to catch early disease. - *Avoid nephrotoxins*: NSAIDs, contrast dye (without adequate hydration), aminoglycosides. - *Manage other risk factors*: Dyslipidemia (statin therapy), anemia, bone-mineral disorders in advanced CKD. **Diabetic Neuropathy** - **Definition & Significance:** Nerve damage from sustained hyperglycemia, affecting sensory, motor, and autonomic nerves. Diabetic neuropathy is the most common complication of diabetes and a major cause of disability. - **Types:** - *Distal Symmetrical Sensorimotor Neuropathy* (most common): Affects feet and legs symmetrically; patients experience numbness, tingling, "pins and needles," and eventually loss of protective sensation. This loss of sensation is dangerous: patients don't feel pressure, temperature, or pain, so minor foot injuries (blisters, cracks, nails cutting skin) go unnoticed and become infected. Combined with poor circulation (from macrovascular disease), minor foot injuries progress to ulcers and amputation. Annually, ~5% of diabetics with sensory neuropathy develop foot ulcers; lower-limb amputation is 10–15 times more common in diabetics than non-diabetics. - *Autonomic Neuropathy*: Affects automatic body functions—gastroparesis (delayed stomach emptying, causing bloating, nausea), orthostatic hypotension (dizziness on standing from blunted baroreceptor reflexes), erectile dysfunction, silent myocardial infarction (MI without typical chest pain because nerves don't transmit pain), and abnormal sweating patterns. - **Prevention & Management:** Tight glycemic control slows progression. Symptomatic relief includes gabapentin, pregabalin (for pain), and duloxetine. In autonomic neuropathy, management addresses specific symptoms (eating small, frequent meals for gastroparesis; compressive stockings/increased salt intake for orthostatic hypotension). Foot care is paramount (see foot care section below). **MACROVASCULAR COMPLICATIONS:** Macrovascular disease (atherosclerosis of large arteries) is accelerated by diabetes and is the leading cause of death in diabetics. Diabetes accelerates atherosclerosis through hyperglycemia-induced endothelial dysfunction, inflammation, dyslipidemia, and thrombosis. Diabetics have 2–4 times the risk of coronary artery disease, stroke, and peripheral vascular disease compared to non-diabetics. Importantly, diabetics often have **atypical or silent presentations** of acute coronary syndrome (ACS) due to autonomic neuropathy (which impairs pain sensation); a diabetic can have a MI without chest pain, presenting instead with dyspnea, nausea, or fatigue. **Coronary Artery Disease (CAD) and Myocardial Infarction (MI):** Diabetes is itself considered a "CAD risk equivalent," meaning that a diabetic without prior MI has the same risk as a non-diabetic with prior MI. Preventive measures include tight glycemic control, aggressive cholesterol management (statin therapy), antihypertensive agents, aspirin (if no contraindications), and lifestyle modification. **Cerebrovascular Disease (Stroke):** Diabetics have 2–4 times the risk of ischemic or hemorrhagic stroke. Risk factors and prevention are similar to CAD. **Peripheral Vascular Disease (PVD):** Atherosclerosis of leg arteries causes claudication (calf pain with walking), rest pain, and tissue loss/amputation. Combined with sensory neuropathy (loss of protective sensation), diabetic PVD is the leading indication for lower-limb amputation in developed countries. **FOOT COMPLICATIONS & ULCERS:** Diabetic foot disease is a major and highly preventable source of morbidity. The triad of (1) sensory neuropathy (loss of pain/pressure sensation), (2) motor neuropathy (muscle atrophy and altered gait), and (3) vascular disease (poor circulation) makes feet exquisitely vulnerable to injury, infection, and amputation. **Prevention of Foot Complications – Critical Nursing Content:** 1. **Daily Foot Inspection:** The patient should examine his or her feet every day using a mirror to see the soles and between toes. Look for: - Redness, swelling, warmth - Blisters, cuts, cracks, corns, calluses - Signs of infection (pus, drainage) - Changes in color (pale, blue, black—signs of ischemia) - Any wound, however minor, should be reported immediately. - Use proper lighting and inspect between toes carefully. 2. **Gentle Foot Hygiene:** - Wash feet daily with warm (not HOT) water and mild soap; check water temperature with your hand or elbow (neuropathy means patients can't sense excessive heat and will burn themselves). - **NEVER use hot water bottles, heating pads, or soak feet in hot water** (risk of burn injury from impaired temperature sensation). - Dry thoroughly, especially between toes (prevents fungal/bacterial overgrowth). 3. **Proper Footwear:** - Wear well-fitting, closed shoes at all times; **NEVER go barefoot** (even in the home, risk of injury). - Shoes should have cushioned soles and adequate support; avoid high heels and narrow-toe shoes. - Inspect inside of shoes before putting them on for debris, stones, or objects. - Break in new shoes gradually; wear thick socks to reduce friction. - In the Philippine climate, rubber thongs/flip-flops offer minimal protection; proper closed shoes are preferable. 4. **Toenail Care:** - Cut nails **STRAIGHT ACROSS** (not curved corners, which can cause ingrown toenails). - Use a nail file to smooth edges; avoid sharp corners. - **DO NOT attempt to cut ingrown toenails yourself**; see a podiatrist. 5. **Moisturize Dry Skin:** - Apply lotion to feet (but NOT between toes, where moisture can cause maceration and infection). - Dry, cracked skin is a portal for infection. 6. **Avoid Trauma:** - Don't cut corns or calluses yourself; see a podiatrist. - Avoid stepping on hard/rough surfaces. - Don't use corn removers or chemical treatments without professional guidance. 7. **Seek Immediate Care for Any Wound:** - Any cut, blister, sore, or unusual finding should be evaluated by a healthcare provider. - Do NOT ignore "minor" injuries; in the context of neuropathy and vascular disease, they can become serious quickly. **What to Avoid:** - **NEVER use heating pads or hot water bottles on feet** (risk of severe burns from impaired temperature sensation). - **NEVER self-treat ingrown toenails, corns, or calluses** (risk of infection and amputation). - **NEVER walk barefoot** (risk of injury). - **NEVER sit with legs crossed for prolonged periods** (impairs circulation to lower legs). - **NEVER smoke** (worsens circulation). **Treatment of Foot Ulcers:** Once a foot ulcer develops, aggressive treatment is needed to prevent infection and amputation: - Thorough wound assessment and classification (using the Wagner Classification or PEDIS classification). - Offloading (removing pressure from the ulcerated area via special shoes, casts, or bed rest). - Debridement of necrotic/infected tissue. - Topical wound care and moisture-balanced dressings. - Treatment of infection (antibiotics if indicated; cultures obtained). - Vascular assessment and intervention if circulation is severely impaired. - In the Philippines, access to advanced wound care, podiatry, and vascular surgery may be limited; early recognition and referral to tertiary centers are crucial. **SCREENING & PREVENTION SUMMARY:** | Complication | **Screening Test** | **Frequency** | **Prevention** | |---|---|---|---| | **Retinopathy** | Dilated eye exam | Annually (more frequently if abnormality found) | Tight glucose control, BP control, annual eye exams | | **Nephropathy** | Serum creatinine, eGFR, urine albumin-to-creatinine ratio | Annually | Tight glucose control, tight BP control, ACE-I/ARB, avoid nephrotoxins | | **Neuropathy** | Clinical exam (monofilament test for sensation), EMG if needed | Annually | Tight glucose control, foot care, pain management | | **Foot Disease** | Visual exam, monofilament test | Annually (more frequently if abnormality found) | Daily foot inspection, proper footwear, nail care, immediate care for wounds | | **CAD/Stroke** | EKG, stress test, carotid ultrasound if indicated | As clinically indicated | Tight glucose control, statin therapy, BP control, aspirin, lifestyle modification | **Philippine Health Context:** In the Philippines, chronic complication screening is often limited by: - Lack of access to ophthalmology services (especially in rural areas); patients may present with advanced retinopathy. - High prevalence of nephropathy and ESRD related to diabetes; dialysis services are available but expensive. - Limited access to podiatry; foot ulcers and amputations are common preventable complications. - Health promotion and patient education on prevention are critical nursing roles; foot care teaching and annual screening referrals can prevent many complications.

A common clinical scenario in diabetes is a patient with elevated fasting (morning) blood glucose despite apparently good glucose control the rest of the day. Distinguishing between the **Somogyi phenomenon** and the **dawn phenomenon** is critical because the treatment approaches are opposite: one requires reducing insulin (Somogyi), while the other may require increasing insulin (dawn). This is high-yield NLE content and is frequently tested. **SOMOGYI PHENOMENON ("Rebound Hyperglycemia"):** Pathophysiology: The Somogyi phenomenon occurs when the patient experiences **unrecognized nocturnal hypoglycemia** (low blood glucose during the night, typically 2–3 a.m.), which triggers a strong counter-regulatory response (epinephrine, cortisol, glucagon release). These hormones rapidly raise blood glucose, resulting in **morning hyperglycemia** (high fasting glucose), despite the fact that glucose was actually LOW during the night. The body has overcorrected in response to the hypoglycemic stimulus. Mechanism: 1. Evening insulin dose is too high or administered incorrectly → glucose drops during sleep. 2. Patient sleeps through the hypoglycemia (no awareness because it occurs while sleeping; autonomic symptoms are not noticed). 3. Counter-regulatory hormones surge → hepatic glucose release increases sharply. 4. Result: morning glucose is HIGH (rebound hyperglycemia), even though the patient had low glucose hours earlier. Characteristic Presentation: - **Fasting (morning) glucose is HIGH.** (Example: 220 mg/dL) - **Patient may report nightmares, restless sleep, or excessive sweating during the night** (sympathetic symptoms of hypoglycemia). - **If a glucose reading is available from 2–3 a.m., it will show LOW glucose** (typically <70 mg/dL, often 40–60 mg/dL or lower), confirming the nocturnal hypoglycemia. - **Patient may report no symptoms** (especially if on insulin for years and has lost hypoglycemia awareness). Risk Factors: - Evening insulin dose (especially NPH or long-acting insulin given in the evening) is too high. - Skipped or delayed bedtime snack. - Unusual physical activity in the evening without corresponding reduction in insulin. - Alcohol consumption in the evening (alcohol potentiates insulin action and can cause delayed hypoglycemia). Management of Somogyi Phenomenon: - **REDUCE the evening insulin dose** by 10–20% to prevent nocturnal hypoglycemia. - **Add a bedtime snack** with complex carbohydrates and protein (e.g., whole-grain toast with peanut butter, yogurt, or a glass of milk) to sustain glucose overnight. - **Check glucose at 2–3 a.m. for 1–2 nights to confirm nocturnal hypoglycemia** (if available; CGM makes this easier). - **Counsel on avoiding evening alcohol and excessive late-day activity** without compensatory carbohydrate intake or insulin reduction. **DAWN PHENOMENON:** Pathophysiology: The dawn phenomenon is an entirely different mechanism: **natural early-morning hormone surge** (from cortisol, growth hormone, and catecholamine release in response to the normal circadian rhythm and stress of waking). This hormonal surge increases hepatic glucose output starting around 4–6 a.m., resulting in morning hyperglycemia. Critically, **there is no preceding hypoglycemia**—the fasting glucose is elevated due to increased hepatic production, not a rebound from low glucose. Characteristic Presentation: - **Fasting (morning) glucose is HIGH.** (Example: 220 mg/dL) - **If a glucose reading is available from 2–3 a.m., it will show NORMAL or HIGH glucose** (e.g., 120–150 mg/dL), NOT low. - **No nightmares, sweating, or nocturnal symptoms** (because glucose was never low). - **Often seen in longer-standing diabetes** and particularly in patients on basal-bolus insulin regimens. Risk Factors: - Natural circadian variation in cortisol and growth hormone. - Inadequate basal insulin coverage (especially basal-bolus regimens with insufficient long-acting insulin). - Later in diabetes course when insulin resistance increases. Management of Dawn Phenomenon: - **INCREASE the basal (long-acting) insulin** dose or shift the timing of the basal insulin (e.g., move NPH from evening to bedtime if it was given earlier; consider switching to a long-acting once-daily insulin like glargine; or add a second dose of basal insulin for added early-morning coverage). - **Add rapid-acting insulin at breakfast** if needed to cover the morning hyperglycemia. - Do NOT reduce insulin (this would worsen fasting hyperglycemia). - Consider adding an oral agent with a different mechanism if appropriate. **Somogyi vs. Dawn — Comparison Table:** | Feature | **Somogyi Phenomenon** | **Dawn Phenomenon** | |---|---|---| | **Mechanism** | Nocturnal hypoglycemia → counter-regulatory hormone surge → rebound high glucose | Natural early-morning hormone surge (cortisol, growth hormone) → hepatic glucose output ↑ | | **2–3 a.m. Glucose** | **LOW** (<70, often <60 mg/dL) | **NORMAL or HIGH** (120–150+ mg/dL) | | **Morning Glucose** | HIGH (rebound hyperglycemia) | HIGH (from hormone surge) | | **Nocturnal Symptoms** | Nightmares, restless sleep, sweating, tremor | **ABSENT** (no hypoglycemia) | | **Cause** | Evening insulin too high, inadequate snack, alcohol, evening activity | Insufficient basal insulin, natural circadian hormone surge | | **Treatment** | **REDUCE evening insulin** OR add bedtime snack | **INCREASE basal insulin** OR adjust timing | | **Key Diagnostic Test** | **Check glucose at 2–3 a.m.** — will be LOW (confirms Somogyi) | **Check glucose at 2–3 a.m.** — will be normal/high (confirms dawn) | **Clinical Example:** **Case 1: Somogyi Phenomenon** A 35-year-old woman with Type 1 diabetes on basal-bolus insulin (glargine 20 units at bedtime + rapid-acting insulin with meals) reports her fasting glucose is consistently 200–220 mg/dL, despite good control during the day (glucose 120–150 mg/dL at lunch and dinner). She mentions she often has vivid nightmares and wakes sweating. Suspicion is Somogyi. Her 3 a.m. glucose (checked via alarm) is 42 mg/dL—confirms nocturnal hypoglycemia. The basal insulin (glargine) is reduced from 20 to 17 units, and a bedtime snack (banana + peanut butter) is added. Follow-up 3 a.m. glucose is now 85 mg/dL, and fasting glucose improves to 140 mg/dL—Somogyi successfully managed. **Case 2: Dawn Phenomenon** A 62-year-old man with Type 2 diabetes on basal insulin (NPH 15 units at bedtime) has a fasting glucose of 180–200 mg/dL, but daytime glucose is controlled (120–150 mg/dL). He reports no nightmares or night sweating. A 3 a.m. glucose check shows 140 mg/dL—NOT low. Diagnosis is dawn phenomenon (natural hormone surge at dawn, not rebound from low glucose). NPH is increased to 20 units, and consideration is given to switching to a long-acting once-daily insulin (glargine) for smoother 24-hour coverage. Fasting glucose improves to 130 mg/dL. **Practical NLE Tips:** - If the question describes **nocturnal symptoms (nightmares, sweating) or a LOW 3 a.m. glucose**, think Somogyi → **REDUCE insulin or add snack.** - If the question describes **NO nocturnal symptoms and a NORMAL/HIGH 3 a.m. glucose**, think dawn phenomenon → **INCREASE basal insulin or adjust timing.** - The **3 a.m. glucose check is the gold standard test** to differentiate the two; modern CGM systems make this much easier. - **Metformin and other non-insulin agents do not cause Somogyi** (no hypoglycemia stimulus); Somogyi and dawn are primarily issues for insulin-treated patients.

Sick days (illness from any cause—infection, injury, surgery, stress) are a critical high-risk period for diabetics. Illness raises stress hormones (cortisol, epinephrine) that increase blood glucose and increase demand for insulin, even if the patient is eating less or not eating at all. Many diabetics (and unfortunately, some healthcare providers) mistakenly believe that if they are not eating, they should skip their insulin—a dangerous error that precipitates DKA. Comprehensive sick-day management education is a cornerstone of diabetes care and is frequently tested on the NLE. **Core Sick-Day Principles:** **1. NEVER Skip Insulin** Illness RAISES glucose; even if appetite is poor or the patient is not eating, insulin demand increases. Skipping insulin during illness is the most common trigger of DKA. The patient should: - Continue taking their usual insulin doses (and may even need MORE insulin if glucose is elevated). - Check blood glucose more frequently than usual (every 2–4 hours or use continuous glucose monitoring). - If glucose is high (>250 mg/dL), contact the healthcare provider for insulin adjustment guidance. **2. Maintain Hydration** Illness causes fluid loss through sweating, vomiting, diarrhea, and osmotic diuresis (from high glucose). Dehydration worsens hyperglycemia and can precipitate HHNS. The patient should: - Drink fluids regularly, even if not eating solid food: water, sugar-free tea, broth, sugar-free electrolyte drinks (NOT regular soda or juice, which will raise glucose further). - Target at least 8 oz of fluid per hour while awake. - Monitor urine output (dark urine suggests dehydration). **3. Continue Carbohydrate Intake When Possible** If the patient can tolerate oral intake, small frequent meals or snacks with carbohydrates should be consumed to prevent hypoglycemia, especially if taking insulin. - **If the patient CAN eat:** Small frequent meals (every 2–3 hours) with carbohydrates and protein. Examples: broth-based soup with crackers, applesauce, yogurt, toast with honey, banana, pudding, jello (regular, not sugar-free). The goal is ~45–50 grams of carbohydrate per meal and 15 grams per snack. - **If the patient CANNOT eat:** Liquid carbohydrates should be used to prevent hypoglycemia: juice, regular soda (not diet), honey, popsicles, or commercial glucose drinks. However, the patient's glucose must still be monitored, and insulin may be adjusted down if the patient is taking insulin AND not eating, though insulin is typically NOT omitted. **4. Monitor Blood Glucose Frequently** - Check glucose every 2–4 hours (or hourly if severely ill or if using a continuous glucose monitor with frequent alerts). - Test for **urine or blood ketones** if glucose is >240 mg/dL or if the patient has symptoms of DKA (nausea, vomiting, abdominal pain, fruity breath, rapid breathing). - Keep a record of glucose readings and insulin doses taken. **5. Know When to Seek Medical Care** The patient should contact a healthcare provider (or go to the emergency department) IMMEDIATELY if: - **Blood glucose remains >250 mg/dL for >2 consecutive checks** or continues rising despite insulin. - **Positive urine or blood ketones** (sign of metabolic stress; DKA risk). - **Vomiting or diarrhea lasting >2 hours** (risk of dehydration and electrolyte loss). - **Chest pain, shortness of breath, severe abdominal pain** (possible MI, infection, DKA). - **Fruity breath, rapid/difficult breathing, confusion** (DKA warning signs). - **Severe headache, vision changes, inability to wake** (possible stroke or severe metabolic derangement). - **Signs of infection** (fever, chills, cough, dysuria) that do not improve with rest and fluids. - **Inability to keep down any fluids or food for >4 hours** (risk of severe hypoglycemia if taking insulin). **Medication Management During Illness:** **Insulin Users:** - Continue all insulin doses as prescribed. - If blood glucose is >250 mg/dL, additional regular insulin may be needed; the patient should have a "sick-day insulin adjustment plan" prepared by their healthcare provider in advance (e.g., "If glucose is 250–300, take 2 extra units of regular insulin; if >300, take 4 extra units"). - **Do not reduce insulin because the patient is not eating.** **Type 2 DM on Oral Agents:** - Metformin: If the patient is vomiting, has severe diarrhea, or is becoming dehydrated, **metformin should be held** (risk of lactic acidosis). Resume when oral intake resumes and hydration is adequate. - Sulfonylureas (glipizide, glyburide): Continue as prescribed, but monitor for hypoglycemia. If the patient is not eating and glucose is dropping, the dose may need to be reduced or skipped to prevent hypoglycemia. - SGLT2 inhibitors: Should be **held during acute illness** (risk of euglycemic DKA). - DPP-4 inhibitors and GLP-1 agonists: Usually continued, but GI side effects may worsen during illness. - Insulin: If the Type 2 patient is on insulin, same rules apply as above. **Contraindications & Cautions:** - **NSAIDs:** While commonly used for pain/fever, NSAIDs can precipitate acute kidney injury and should be used cautiously (or avoided) in dehydrated or acutely ill diabetics, especially those with underlying CKD. Acetaminophen is safer for fever/pain. - **Steroids (if prescribed for illness):** Can significantly elevate blood glucose; insulin adjustments are usually needed. **Pre-Illness Planning:** Ideally, during clinic visits, the healthcare provider should: - Discuss sick-day management and provide written instructions. - Develop a "sick-day insulin adjustment plan" (specific insulin doses for different glucose levels). - Provide prescriptions for supplies: urine/blood ketone testing kits, glucose testing strips, extra lancets. - Give the patient a phone number or clinic name to call if questions arise during illness. - Counsel on when to go to the emergency department. **PATIENT EDUCATION ON DIABETES SELF-MANAGEMENT:** Beyond sick-day management, comprehensive diabetes education is the foundation of good outcomes. Key topics include: **Glucose Monitoring:** - How to use a blood glucose meter: proper hand hygiene, adequate blood drop, meter calibration, and recording results. - Target glucose ranges: typically 80–130 mg/dL fasting, <180 mg/dL postprandial (after meals). - Importance of regular monitoring (frequency depends on medication: insulin users should check more frequently). - Continuous glucose monitoring (CGM) systems: how they work, advantages, and limitations. **Nutrition & Meal Planning:** - Carbohydrate counting (especially important for insulin users): understanding portions and how different foods affect glucose. - Glycemic index and glycemic load of foods (low-glycemic foods cause less rapid blood glucose spikes). - Portion control and balanced meals (protein, healthy fat, fiber with carbohydrates). - Consistent meal timing (especially for patients on fixed insulin schedules). - Limiting simple sugars, sugar-sweetened beverages, and processed foods. - In the Philippine context: adapting traditional Filipino dishes (rice, adobo, lumpia) to fit diabetes management; portion-control of rice (key staple); choosing brown rice or complex carbs when possible. **Physical Activity:** - Benefits: improves insulin sensitivity and glucose control, aids weight loss, improves cardiovascular health. - Frequency & intensity: target 150 minutes of moderate aerobic activity per week (or 75 minutes of vigorous activity), plus resistance training 2–3x weekly. - Insulin/carbohydrate adjustments before and after exercise to prevent hypoglycemia. - Always carry a fast-acting carbohydrate source during exercise. - Proper footwear and foot care during physical activity (for those with neuropathy). **Weight Management (Especially Type 2):** - Even a 5–10% weight loss can improve insulin sensitivity and reduce A1c. - Combination of diet and physical activity is most effective; medications (GLP-1 agonists, SGLT2 inhibitors) can support weight loss. - Behavioral strategies: keeping a food diary, identifying trigger foods, gradual lifestyle changes rather than crash diets. **Stress Management:** - Stress hormones (cortisol) raise blood glucose; chronic stress worsens diabetes control. - Techniques: deep breathing, meditation, yoga, regular exercise, adequate sleep, social support. - Recognition that major life stressors (job loss, bereavement, relationship problems) often precipitate poor glycemic control and may require additional diabetes support. **Medication Compliance:** - Taking medications exactly as prescribed (not skipping doses, especially insulin). - Understanding why each medication is prescribed and its potential side effects. - Refill prescriptions on time to avoid running out. - Organizing medications (pill organizers, phone reminders, etc.). **Psychosocial Support:** - Diabetes is demanding; depression and diabetes distress are common and should be screened for and addressed. - Referral to mental health services, diabetes support groups, or diabetes educators as needed. - Recognition that poor glycemic control is not always a moral failing; many factors (genetics, life stressors, medication access) influence outcomes. **In the Philippine Healthcare Context:** Diabetes education in the Philippines often takes place in: - Public health centers and municipal hospitals (where nurses are often the primary educators). - Barangay health stations (where BHWs provide basic health promotion). - NGO-run diabetes clinics and community programs. - Private practices (less accessible to the poor). Challenges include: - Limited health literacy; some patients have little formal education. - Language barriers; health education in English may not be understood by Tagalog/regional language speakers. - Limited resources for printed materials and glucose monitors. - High cost of medications and supplies, limiting access. - Competing priorities (food security, housing) that may overshadow diabetes management. - High prevalence of family-based decision-making (patient education should involve family members, especially for insulin administration). **Culturally Tailored Education Strategies:** - Teach in the patient's primary language (Tagalog, Ilocano, Cebuano, etc.). - Use simple, clear language and visual aids (pictures, drawings) for those with low literacy. - Involve family members (spouse, adult children, caregiver) in education sessions. - Adapt examples to Filipino context: discuss portion sizes of traditional foods, barriers to physical activity in the patient's neighborhood, how to afford medications. - Use barangay health workers and community health volunteers (who are trusted local figures) to reinforce education and support adherence. - Incorporate traditional health beliefs (if the patient believes in herbal remedies or alternative approaches, explore these respectfully and provide evidence-based guidance). - Emphasize immediate benefits of good control (feeling better, fewer doctor visits, fewer complications) in addition to long-term prevention, as some patients may be more motivated by short-term improvements.